Cefoperazone in the treatment of infections in cancer patients.
Cefoperazone appears to be one of the cephalosporins with the most promise in granulocytopenic patients, regardless of whether it is used in combination or as monotherapy. It has the broad spectrum of antimicrobial activity necessary to inhibit the organisms commonly encountered in patients with cancer, as well as the ability to achieve high serum levels for sustained periods of time. Administration of cefoperazone should provide effective therapy in the overall management of most infections encountered in patients with neoplastic diseases.
D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002438:Cefoperazone / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D009369:Neoplasms / Q000150:complications*
D002438:Cefoperazone